On November 27, 2024, 36Kr, a leading technology venture capital media in China, released the "WISE2024 Commercial King Series Annual Enterprise List". With its leading innovative practices in AI pharmaceuticals, excellent commercial performance, and high growth potential,"MindRank" Selected as "WISE2024 Business King of the Year - Most Valuable Company in Artificial Intelligence".Other leading companies selected in the same period include iFlytek, Zhipu AI, Baichuan Intelligence, MoonShot, among others in the large model track, as well as Moore Threads and Black Sesame Technologies, among others in the intelligent hardware track.
As the global economy calls for recovery, innovation has become the core driving force for the survival and development of enterprises, as well as the ballast stone to deal with various uncertainties in the environment. In October this year, 36Kr specially launched the "WISE2024 Business King Series Annual Enterprise List" research, setting up two major categories: "WISE2024 Business King Annual Enterprise with the Most Business Value" and "WISE2024 Business King Annual Enterprise with the Most Business Potential", covering nine new economic fields.
After several rounds of selection from hundreds of submitted companies, and a comprehensive evaluation of enterprises' innovation ability, commercialization ability, capital capability, core competitiveness, combined with the opinions of professional analysts, 36Kr ultimately selected companies in artificial intelligence, cutting-edge technology, and other fields that are able to...Representative companies that provide significant impetus for the development of China's frontier industries and offer innovative momentum for global economic growth.
WISE2024 Business King Annual Most Valuable Companies in Artificial Intelligence Field - Full List:
As a representative AI pharmaceutical company in China, "MindRank" is always committed to pushing the boundaries of AI-empowered drug discovery technology through continuous innovation. The company has independently developed and built an internationally leading industrial-grade one-stop AI-driven innovative drug R&D platform, which can save 50% or more of the preclinical R&D cycle and cost for new drugs, effectively assisting in the development of innovative drugs targeting difficult-to-drug and novel targets.
In recent years, as the artificial intelligence industry has comprehensively moved from foundational model research and development to application implementation, "MindRank" has innovatively introduced large-scale AI model technology based on high-quality data and cutting-edge algorithm accumulation, andExtend the AI + small molecule drug R&D technology capabilities to different modal fields such as molecular glue, PROTAC, macromolecules, and ADC.The platform's capabilities have been validated in multiple collaboration projects with Chinese listed pharmaceutical companies and multinational pharmaceutical companies. Currently, with the assistance of the AI platform, "MindRank"MindRank's self-developed GLP-1RA small molecule oral drug MDR-001 is proceeding smoothly in Phase IIb clinical trials.Multiple innovative drugs targeting tumors and metabolism are in the IND-Enabling stage.
About 36Kr
36Kr is a new economy service group with media as its flagship, committed to the long-term coverage, service, and companionship of participants in China's new economy. Its mission is to enhance Chinese business efficiency and enable some people to see the future first. Upholding the development philosophy that "the core of media will never change, while the boundaries of media are always expanding," 36Kr serves as a value-connecting link for six major communities: startups, internet giants, traditional enterprises, investment institutions, local governments, and individual users. Over its 13 years of establishment, 36Kr has accumulated resources from over 800,000 companies, covering more than 100 industry sectors. Its reports encompass 98% of venture capital investment enterprises, and 93% of financing events in China are first reported by 36Kr, extensively covering both primary and secondary markets, as well as toB and toC fields.